The effect of treatment of hypercholesterolemia on risk of macular edema

The effect of treatment of borderline hypercholesterolemia on risk of macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201709207466N5

Enrollment

Registered

2017-10-31

Start date

2017-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Diabetes mellitus

Interventions

Intervention 1: Daily, for 3 months, Atorvastatin 20 mg. Intervention 2: Daily, for 3 months, Placebo.

Treatment - Drugs

Daily, for 3 months, Atorvastatin 20 mg

Daily, for 3 months, Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diabetic retinopathy; Borderline hypercholesterolemia; and having informed consent; Exclusion Criteria: CSME macular edema; proliferative Diabetic retinopathy;

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Macular Edema. Timepoint: Baseline, 3 Months later. Method of measurement: Test.	—

Secondary

Measure	Time frame
Retinopathy. Timepoint: Baseline, 3 months Later. Method of measurement: Test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ali Arash Anoushirvani

Arak University of Medical Sciences

dr.anoushirvani@arakmu.ac.ir+98 86 3417 3645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026